Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Loading...
Community
/
Germany
/
Pharmaceuticals & Biotech
/
Evotec
EVT
Evotec
Global Healthcare Trends And AI Will Expand Outsourced Discovery
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
24 Aug 25
Updated
24 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
€12.00
50.5% undervalued
intrinsic discount
24 Aug
€5.94
1Y
-7.2%
7D
-3.3%
Loading
1Y
-7.2%
7D
-3.3%
Author's Valuation
€12.0
50.5% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
€12.0
50.5% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-180m
1b
2014
2017
2020
2023
2025
2026
2028
Revenue €1.1b
Earnings €122.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
8.99%
Life Sciences revenue growth rate
0.32%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
5.79%
Calculation
€122.95m
Earnings '28
x
20.56x
PE Ratio '28
=
€2.53b
Market Cap '28
€2.53b
Market Cap '28
/
178.21m
No. shares '28
=
€14.18
Share Price '28
€14.18
Share Price '28
Discounted to 2025 @ 5.77% p.a.
=
€11.99
Fair Value '25